글로벌 편두통 치료 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

편두통은 쇠약해질 수 있는 흔한 뇌 질환입니다. 두통은 모든 일반 진료 방문의 4.4%, 모든 의료 병원 입원의 거의 5%, 신경과 외래 진료의 20% 이상을 차지합니다. 편두통은 약 20%의 사람들에게 일생의 어느 시점에서 영향을 미치며, 역학 연구에 따르면 서유럽 인구의 4.5%가 한 달에 최소 15일은 두통을 겪고 있으며, 전 세계 연구에 따르면 전 세계 인구의 약 1%가 만성 편두통을 겪고 있습니다.

Data Bridge Market Research는 2021년에 23억 8천만 달러였던 편두통 치료 시장이 2029년까지 46억 7천만 달러로 급증할 것으로 분석했으며, 2022년부터 2029년까지 예측 기간 동안 8.80%의 CAGR을 보일 것으로 예상합니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자, 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크도 포함되어 있습니다.

보고 범위 및 시장 세분화

Market Definition

Migraine is a devastating neurological disease characterized by recurrent severe throbbing head pain attacks that can last for more than three days. The headaches, which are usually unilateral, can last from four hours to three days. Other symptoms such as nausea, increased sensitivity to sound (phonophobia), vomiting, increased sensitivity to light (photophobia), tingling or numbness in the extremities or legs, sweating, and diarrhoea are frequently linked with pain.

Migraine Treatment Market Dynamics

Drivers

• Increase in migraine prevalence and diagnosis

One of the major factors driving market expansion is a huge increase in migraine cases. Also, the market is benefiting from improved reimbursement policies for migraine treatments and the rising demand for precision medicines. Rising demand for electrical nerve stimulating devices to treat migraines and the expected approval of new classes of late-stage pipeline drugs with higher clinical efficacy, such as the introduction of calcitonin gene-related peptide (CGRP) monoclonal antibodies, are propelling market growth.

• Significant progress is being made in the preventative treatment of chronic migraine

The significant advancements should reconsider the approaches to this devastating disease and empower us to remain observant and continue scientific clinical research and also keeping in mind that only a common, shared clinical and scientific management strategy will improve chronic migraine detection. This distinguish phenotypes and biological markers, shed light on neglected clinical governance areas. It is up to us to ensure that novel and developing treatment alternatives, such as OBT-A and anti-CGRP monoclonal antibodies, are exploited to their full potential within a broader preventative culture to drastically minimise the personal, societal, and economic costs of this deadly disease.

• Growing awareness regarding migraine

The increased awareness of migraine and the multiple treatment choices available are the primary drivers of the global migraine treatment market growth in the near future. A number of organisations, like the American Headache and Migraine Association, are attempting to raise awareness of migraine by developing programmes and providing assistance to patients in order to raise knowledge about the disease and other headache diseases. A lot of vendors are going to invest in migraine medications research and development (R&D) as a result of the rising number of migraine incidences and unmet demands in the global migraine treatment market. As a result, the worldwide migraine medications market is expected to grow in the forecast period of 2022 to 2029.

Opportunities

Migraine treatment includes features such as increased research and development (R&D) investment leading to pipeline products, which will result in manufacturers launching new products into the market, increasing demand, and technological advancement for the treatment of acute migraine has increased. Various research studies are now underway, which are likely to give producers a competitive advantage in developing new, innovative, and improved migraine treatment medications and other opportunities in the migraine treatment market.

Restraints/Challenges

However, alternative therapies such as homeopathy and limitations of current migraine therapies, decline in clinical visits and procedural treatment of migraines due to social distancing norms are expected to restrain the market growth in the forecast period 2022 to 2029.

This migraine treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the migraine treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Migraine Treatment Market

COVID-19's neurologic signs point to the virus entering the neurological system via the olfactory groove or the circulation. COVID-19 mortality has been linked to cardiac and pulmonary illnesses in numerous studies. Furthermore, migraine causes a larger burden of vascular disorders, putting migraine sufferers at a higher risk of poor COVID-19 outcomes. A migraine attack can be triggered by COVID-19 acute symptoms such as fever, sleep difficulty, and dehydration. COVID-19 headaches were described as pulsing, pressing, or stabbing in nature, and were mostly bilateral, lasting longer, resistant to analgesia, and more common in males. This makes migraine sufferers particularly vulnerable to the pandemic's long-term and indirect consequences, such as low mood, post-viral exhaustion, and anxiety.

Recent Development

• According to Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc., Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, earned a favourable opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) in February 2022. The 75 mg dose of Rimegepant (available as an orally dissolving tablet) is suggested for marketing authorization for the acute treatment of migraine with or without aura in adults and the preventative treatment for episodic migraine in adults who experience at least four migraine attacks per month.
• In January 2022, Elyxyb (celecoxib oral solution) is a novel fast-acting liquid from BioDelivery Sciences. It's one of the first FDA-approved ready-to-use oral treatments for individuals suffering from acute migraine with or without aura.

Global Migraine Treatment Market Scope

The migraine treatment market is segmented on the basis of type, treatment, route of administration, product, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Episodic
• Migraine with Aura
• Chronic
• Others 

Treatment

• Acute/Abortive Treatment
• Preventive/prophylactic Treatment 
• Non-Pharmacological Therapies and Devices

Route of Administration

• Oral
• Parenteral

 Product

• Prescription
• Over The Counter

Type

• Branded
• Generic

 End-User

• Hospitals
• Clinics
• Homecare
• Others

Distribution Channel

• Hospital-Based Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Migraine Treatment Market Regional Analysis/Insights

The migraine treatment market is analysed and market size insights and trends are provided by country, type, treatment, route of administration, product, distribution channel and end-user as referenced above.

The countries covered in the migraine treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is a dominating region in the global migraine treatment market. The presence of a well-established pharmaceutical sector in the region is an important reason in North America's strong position in the global migraine treatment market. Furthermore, due to a great understanding of the dangers of migraine and how it impacts quality of life, there is a substantial need for migraine drugs in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Healthcare Infrastructure growth Installed base and New Technology Penetration

The migraine treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for migraine treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the migraine treatment market. The data is available for historic period 2010-2020.

Competitive Landscape and Migraine treatment Market Share Analysis

The migraine treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to migraine treatment market.

Some of the major players operating in the migraine treatment market are:

• Pfizer Inc. (U.S)
• Eli Lilly and Company (U.S)
• Amgen Inc. (U.S)
• GlaxoSmithKline plc. (U.K)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Allergan (Ireland)
• Abbott (U.S)
• Allodynic Therapeutics, LLC(미국)
• AOBiome(미국)
• 아스트라제네카(영국)
• 오로빈도 파마 USA(미국)
• Bausch Health Companies Inc. (캐나다)
• 바이오하븐제약(미국)
• 베링거인겔하임인터내셔널(독일)
• Catalent, Inc (미국)
• Dr. Reddy's Laboratories Ltd. (인도)
• 임펠제약 주식회사(미국)
• H. Lundbeck A/S(덴마크)
• 머크앤코(미국)

SKU-52137